©The Author(s) 2021.
World J Gastroenterol. Sep 21, 2021; 27(35): 5851-5889
Published online Sep 21, 2021. doi: 10.3748/wjg.v27.i35.5851
Published online Sep 21, 2021. doi: 10.3748/wjg.v27.i35.5851
Table 4 Phase of trial and level of evidence of trial about chemotherapy for resectable and borderline resectable pancreatic ductal adenocarcinoma
| Ref. | Phase of trial | Level of evidence |
| Neoptolemos et al[185] | III | II |
| Oettle et al[186] | III | I |
| Neoptolemos et al[187] | III | I |
| Neoptolemos et al[188] | III | I |
| Conroy et al[189] | III | I |
| You et al[195] | III | II |
| van Roessel et al[198] | IV | II |
| Versteijne et al[202] | III | II |
| Ghaneh et al[205] | II | II |
| Sohal et al[207] | IV | II |
| Labori et al[209] | III | II |
| Schwarz et al[210] | II | I |
| Ettrich et al[211] | II | II |
| Motoi et al[212] | III | II |
| UMIN-CTR Clinical Trial[215] (UMIN000026858) | III | II |
- Citation: Tonini V, Zanni M. Pancreatic cancer in 2021: What you need to know to win. World J Gastroenterol 2021; 27(35): 5851-5889
- URL: https://www.wjgnet.com/1007-9327/full/v27/i35/5851.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i35.5851